Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD) from Numab Therapeutics in an all-cash deal valued at $1.25 bill
Switzerland’s Numab has raised 100 million Swiss francs - around $110 million - in Series C financing to develop bispecific antibodies for cancer and inflammation, with Novo Noldings and HB
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl